VERTEX PHARMACEUTICALS INC / MA 4

Accession 0001209191-14-060592

$VRTXCIK 0000875320operating

View on SEC.gov Company Profile

Filed

Sep 30, 8:00 PM ET

Accepted

Oct 1, 5:16 PM ET

Size

37.2 KB

Accession

0001209191-14-060592

Insider Transaction Report

Form 4

Period: 2014-09-30

VERTEX PHARMACEUTICALS INC / MAVRTX

Pace Megan E

SVP, Corp. Communications

Transactions

Exercise/Conversion
Stock Option (right to buy)
2014-09-30−1,172→ 2,344 total
Exercise: $38.80Exp: 2021-02-02→ Common Stock (1,172 underlying)
Exercise/Conversion
Common Stock
2014-09-30$45.11/sh+17,157$773,952→ 66,086 total
Exercise/Conversion
Common Stock
2014-09-30$83.36/sh+6,875$573,100→ 72,961 total
Sale
Common Stock
2014-09-30$113.08/sh−15,400$1,741,432→ 34,979 total
Sale
Common Stock
2014-09-30$113.90/sh−11,629$1,324,543→ 23,350 total
Sale
Common Stock
2014-09-30$111.32/sh−7,576$843,360→ 72,260 total
Sale
Common Stock
2014-09-30$112.21/sh−21,881$2,455,267→ 50,379 total
Exercise/Conversion
Stock Option (right to buy)
2014-09-30−17,157→ 28,593 total
Exercise: $45.11Exp: 2023-02-04→ Common Stock (17,157 underlying)
Exercise/Conversion
Stock Option (right to buy)
2014-09-30−6,875→ 20,625 total
Exercise: $83.36Exp: 2023-07-29→ Common Stock (6,875 underlying)
Exercise/Conversion
Common Stock
2014-09-30$37.86/sh+3,532$133,722→ 33,679 total
Exercise/Conversion
Common Stock
2014-09-30$38.80/sh+1,172$45,474→ 24,522 total
Exercise/Conversion
Common Stock
2014-09-30$51.75/sh+5,625$291,094→ 30,147 total
Exercise/Conversion
Common Stock
2014-09-30$48.74/sh+15,250$743,285→ 48,929 total
Exercise/Conversion
Stock Option (right to buy)
2014-09-30−5,625→ 1,875 total
Exercise: $51.75Exp: 2021-07-12→ Common Stock (5,625 underlying)
Exercise/Conversion
Stock Option (right to buy)
2014-09-30−3,532→ 4,218 total
Exercise: $37.86Exp: 2022-02-01→ Common Stock (3,532 underlying)
Exercise/Conversion
Stock Option (right to buy)
2014-09-30−15,250→ 15,250 total
Exercise: $48.74Exp: 2022-07-24→ Common Stock (15,250 underlying)

Footnotes (13)

[F1]Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1.
[F10]The option vests in 16 quarterly installments from 07/25/2012.
[F11]The option vests in 16 quarterly installments from 02/05/2013.
[F12]The option vests in 16 quarterly installments from 07/30/2013.
[F13]The option vests in 16 quarterly installments from 02/05/2014.
[F2]Open market sales reported on this line occurred at a weighted average price of $111.32 (range $110.61 to $111.60).
[F3]Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
[F4]Open market sales reported on this line occurred at a weighted average price of $112.21 (range $111.61 to $112.60).
[F5]Open market sales reported on this line occurred at a weighted average price of $113.08 (range $112.61 to $113.59).
[F6]Open market sales reported on this line occurred at a weighted average price of $113.90 (range $113.62 to $114.32).
[F7]The option vests in 16 quarterly installments from 02/03/2011.
[F8]The option vests in 16 quarterly installments from 07/13/2011.
[F9]The option vests in 16 quarterly installments from 02/02/2012.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

VERTEX PHARMACEUTICALS INC / MA

CIK 0000875320

→

Entity typeoperating

IncorporatedMA

Related Parties

filerCIK 0000875320

Filing Metadata

Form type: 4
Filed: Sep 30, 8:00 PM ET
Accepted: Oct 1, 5:16 PM ET
Size: 37.2 KB

View on SEC.gov